Introduction to hospital reimbursement in the Netherlands – Understanding the unique payer-provider relationship
14 Nov 2019, 16:00 CET
Webinar

In this webinar we will provide a introductory training on how reimbursement in hospitals work in the Netherlands. Many of the terms and concepts that are used such as DRG, coverage with evidence development etc. are similar to many other countries. However the dynamics of how the system works is very different due to the particular tri-party set-up, where the patient may choose the insurance company, the insurance company negotiates with the hospital and the government's role is to provide monitoring and controls. This creates a dynamic that is different than most other European countries. 

In this webinar, we will describe the system as well as how the unique way of collaboration is working.

Speaker: Wim Meijer has over 30 years of experience within the healthcare system. After achieving his degree in Microbiology in 1987, he had several roles within healthcare and healthcare related environments. His first role was as a sales representative in Biotechnology products evolving to a product management role in Medical Disposables for Anesthesia and OR, sales and marketing manager Medical Disposables for Blood collecting organizations in Benelux. 

In 2002 he moved to Pharma to become a business development manager for Infliximab, a TNF-α medicine against Rheumatoid Arthritis, Chron’s Disease and Psoriasis. After working with the products he became expert in reimbursement by discussions with Health Insurers. He developed at that time his interest for Market Access. He worked for Shering-Plough and UCB Pharma. He is trained in HTA modeling for Health Economic questions. He has been working with MAQUET for 2 years after a merge with ATRIUM. In this job he was responsible for the Global Market Access and Health Economic challenges for the total Maquet port-folio. 

He has joined several working groups within BVMed (Germ), SNITEM (Fr), NICE (UK) and ISPOR and is working in close collaboration with national authorities like NICE, Inek/IQWiQ, HAS, TLV etc. He started his own company WIMENCO beginning of 2016 and worked with several partners in Life Sciences projects.